Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
Developing PSC-based therapeutics is a complex journey, especially for founders transitioning from academia. Many critical early decisions—often made without full awareness of their downstream impact—can unintentionally hinder the development of an investable, clinically meaningful therapy suitable for broad patient populations.
At Lindville Bio, we provide strategic guidance across all stages of therapeutic development. Our areas of expertise include regulatory strategy, pre-clinical planning, chemistry, manufacturing and controls (CMC), market positioning, communications, fundraising and investor readiness, business operations, and recruitment. Our value stems from direct experience: we’ve navigated this path ourselves and have spent over four years helping numerous iPSC companies do the same.
We offer a flexible, fully insured B2B service that is tailored to your needs—whether you're seeking targeted advice on a specific issue, need an experienced sounding board, or require additional expertise without the cost or commitment of a full-time hire.
Based in the UK, Lindville Bio has deep experience supporting companies seeking regulatory approval in both the US and European markets. Our Principal Consultant, Dr. Stephen Sullivan, brings over two decades of experience in stem cell science and therapeutic development.
Dr. Sullivan began his scientific career with the team that cloned Dolly the Sheep and earned his PhD studying the reprogramming of human somatic cells to pluripotency. He held research fellowships at Cambridge, Harvard, and UCSD, and later completed an MBA focused on the commercialisation of stem cell-based therapies. He served as Director of the Irish Stem Cell Foundation, successfully advocating for stem cell legislation in Ireland. He co-edited and co-authored Human ES Cells: A Practical Handbook (Wiley), and served as Associate Editor of Differentiation, a journal focused on cell fate and reprogramming.
Dr. Sullivan also served as Programme Manager at the Global Alliance for iPSC Therapies (GAiT), where he led international quality standardization efforts, including a global quality assessment across 18 organizations and the publication of critical quality attributes for clinical-grade iPSC lines. He worked at the Scottish National Blood Transfusion Service as a Project Support Officer in Advanced Cell Therapeutics.
Most recently, Dr. Sullivan was Chief Operations Officer and Board Member at iPSirius, a Paris-based immunotherapy company developing off-the-shelf iPSC-derived cancer vaccines. There, at iPSirius, he led operational setup and the initiation of a first-in-human clinical trial for their lead product, IPVAC-1, targeting Stage 3 non-small cell lung cancer.